Life Time Group Holdings Inc. Common Stock vs BIO-TECHNE Corp — how do they compare? Life Time Group Holdings Inc. Common Stock trades at $41.04 (market cap $9.00B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Life Time Group Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Life Time Group Holdings Inc. Common Stock for 1 Days and BIO-TECHNE Corp for 64 Days on average.
| LTH | TECH | |
|---|---|---|
Market Cap | $9.00B | $11.36B |
Volume | 2,696,923 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $45.73 | $72.61 |
52-Week Low | $24.59 | $43.31 |
Typical Hold Time | 1 Days | 64 Days |
Enterprise Value | $13.05B | $11.39B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Life Time operates fitness and lifestyle centers that offer gyms, classes, sports facilities, and wellness services.
Read more on LTH →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →